Mazdutide (5mg) Dosage Protocol
Mazdutide is a novel dual GLP-1/glucagon receptor agonist in clinical development. It combines the metabolic benefits of GLP-1 activation with glucagon's effects on energy expenditure and hepatic glucose output.
Add 1.0 mL bacteriostatic water → 5 mg/mL
3-9 mg once weekly (clinical trial doses)
At 5 mg/mL: 60 units = 3 mg, 180 units = 9 mg
Lyophilized: -20°C; Reconstituted: 2-8°C for up to 4 weeks
| Week | Daily Dose | Units (per injection) |
|---|---|---|
| Weeks 1-4 | 3 mg weekly | 60 units once weekly |
| Weeks 5-8 | 4.5 mg weekly | 90 units once weekly |
| Weeks 9+ | 6-9 mg weekly | 120-180 units weekly |
- 1Draw 1.0 mL bacteriostatic water with a sterile syringe
- 2Inject slowly down the vial wall
- 3Gently swirl until fully dissolved - do not shake
- 4Label with date and concentration, refrigerate immediately
Mazdutide activates both GLP-1 and glucagon receptors. GLP-1 activation reduces appetite and improves glycemic control, while glucagon activation increases energy expenditure and promotes hepatic fat reduction. This dual mechanism may provide enhanced metabolic benefits.
- Dual receptor activation
- Clinical trials show significant weight loss
- May improve liver fat content
- Enhanced metabolic effects vs single agonists
- Ji L, et al. Mazdutide Phase 2 trial results. Lancet Diabetes Endocrinol. 2023
- Innovent Biologics clinical trial data
- Dual GLP-1/glucagon agonist research
Lyophilized
Store at -20°C, protected from light
Reconstituted
Refrigerate at 2-8°C, use within 4 weeks
Titrate slowly to minimize GI side effects
- •Investigational compound - not yet approved
- •Currently in Phase 3 clinical trials
- •Titrate slowly to reduce nausea
- •Similar precautions as other GLP-1 agonists
Disclaimer: This content is intended for research and educational purposes only. Not intended to diagnose, treat, cure, or prevent any disease. All compounds are for research use only. Dosing information is derived from published scientific literature and clinical studies.